Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORP-110
- Development stage
- Unknown
- Lead developer
- OrphoMed
- Modality
- Small Molecules
01
Overview
ORP-110 is an investigational small molecule developed by OrphoMed, Inc. as a **CFTR (cystic fibrosis transmembrane conductance regulator) stimulant** for the treatment of **cystic fibrosis**. It is designed to enhance CFTR function, potentially addressing the underlying defect in chloride ion transport characteristic of the disease. Currently in the **discovery stage**, with preclinical development focused on this rare genetic disorder affecting the lungs and other organs.[7][19]
Beyond the preview
Go deeper on ORP-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORP-110.